111 results about "Cells transplant" patented technology

A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and / or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.

Methods, cells, and compositions of matter are disclosed for performing stem cell transplants in patients that have not been previously immunosuppressed. Specific disclosed are methods of matching, methods of treating the stem cell graft, and use of engraftment-assisting cells and agents.

Apparatus is provided, including a housing (22), configured for insertion into a body of a patient; a photosynthetic oxygen supply (24) configured to supply oxygen; and functional cells (30), coupled to the housing (22). The functional cells (30) are adapted to receive the oxygen and to secrete at least one factor that induces vascularization in a vicinity of the housing (22) when the housing (22) is in the body of the patient. Other embodiments are also described.

The invention relates to methods and materials for enhancing muscle mass or for the treatment of muscle disease in a subject, comprising introducing a cell which has a lower than normal level of myostatin signalling, into the subject.

The present invention has an object to provide a transplant material allowing systemic bone substance improvement to be realized by cell transplant. The present invention teaches to use a transplant material comprising a cell selected from the group consisting of an embryonic stem cell, a mesenchymal stem cell, an osteoblast cell, a preosteoblast, a chondrocyte and a cell having a capability of bone formation through systemic or topical administration for the improvement in bone quality.

The main objects of the present invention, which relates to regenerative medical treatments, are to enable (i) storage and conveyance of harvested or cultured cells without contamination occuring (ii) simple injection of the cells into a living body. To achieve these objects, cells harvested from a living body, or cells obtained by culturing harvested cells, are stored in a syringe-type storage vessel and subsequently transplanted into a living body. It is preferable that at least a part of the storage vessel inner wall in contact with the cells is formed from a cell non-adhesive material. Besides enabling cells in the vessel to take in the oxygen they require to survive, the present invention also enables cells quick and easy transplantation of cells into a living body without a cell detachment process, because cells are prevented from adhering to the inside of the vessel. Further, it is preferable that a stored tissue regeneration composition contains cell culture microcarriers floating in a fluidity medium, and that the cell culture microcarriers are composed of a bioabsorbable material and have cells adhering to their surfaces. Using this kind of tissue regeneration composition, a regenerative treatment can be carried out satisfactorily by simply and quickly transplanting cells from the syringe-type cell storage vessel into a living body without intricate scaffold-related procedures being required.

The present invention provides methods and compositions for tissue regeneration without cell transplantation.

A device and method for neural transplantation in the human brain comprising a microinjector (1), transplantation cannula (2) and bullet guide (16) is disclosed. The microinjector (1) is designed to connect to the proximal end of a syringe barrel (7) and plunger (12) while the transplantation cannula (2) interfaces with the distal end of the syringe barrel (7). In combination, the microinjector (1) and transplantation cannula (2) permit the delivery of multiple cell grafts in a three-dimensional array using a unique spiral technique. The bullet guide (16), which is attachable to a commercially available stereotactic frame, is a multiple channel adapter that functions as a mechanical guiding system for the transplantation cannula (2) and permits plural, spaced deployment of the cannula (2) without adjusting or disturbing the frame.

The present invention generally relates to methods, compositions and uses thereof for enhancing vascularization of a tissue or cell transplant for transplantation into a subject. In particular, one aspect of the present invention provides methods and compositions comprising the use of a population of stromal vascular fraction (SVF) cells to encapsulate or surround a tissue or cell transplant to enhance vascularization of the tissue or cell transplant. Another aspect of the present invention provides methods and compositions for enhancing vascularization of a tissue or cell transplant by combining a population of SVF cells with a tissue or cell transplant to form a transplant mixed with SVF cells. Another aspect provides a composition comprising an engineered corpus cavernosum tissue comprising SVF cells and corpus cavernosum cells, wherein the SVF cells can be mixed with or encasing the corpus cavernosum cells, and methods of uses thereof, for example in method for the treatment of impotence and erectile dysfunction and / or enhance or construct a penis. In some embodiments, the SVF cells can be generically engineered to secrete therapeutic proteins or pro-angiogenic factors.

Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided. Also provided are conditioned media, related compositions, related methods, and related packaging products.

An artificial tendon, ligament, bone and skin panel are provided, made of biocompatible materials and capable of being seeded and eventually coated with selected cell types. Seeded or coated artificial tendon, ligament, bone or skin panels can be shaped and implanted in mammals. Implantable cell growth cages may be seeded with selected cell types and used to produce desired gene expression products within a mammal. Gene expression products may be harvested from transfected animal cells cultured in a cell growth chamber.

The invention provides a method of removing or reducing undifferentiated cells from a differentiated cell population contaminated or having a risk of contamination with undifferentiated cells by contacting a pigment epithelium-derived factor with the differentiated cell population to induce apoptosis of the undifferentiated cells. The invention also provides an agent for cell transplantation therapy, containing a differentiated cell population substantially free of an undifferentiated cell, which is obtained by the method, as well as an agent for inducing apoptosis of an undifferentiated cell, containing a pigment epithelium-derived factor, and combined use of the aforementioned agent for cell transplantation therapy and the aforementioned agent for inducing apoptosis.

Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided.

The present invention generally relates to methods, compositions and uses thereof for enhancing vascularization of a tissue or cell transplant for transplantation into a subject. In particular, one aspect of the present invention provides methods and compositions comprising the use of a population of stromal vascular fraction (SVF) cells to encapsulate or surround a tissue or cell transplant to enhance vascularization of the tissue or cell transplant. Another aspect of the present invention provides methods and compositions for enhancing vascularization of a tissue or cell transplant by combining a population of SVF cells with a tissue or cell transplant to form a transplant mixed with SVF cells. In some embodiments, the SVF cells can be on the surface or embedded within a three-dimensional matrix. In some embodiments, the SVF cells can be generically engineered to secrete therapeutic proteins or pro-angiogenic factors.

The invention discloses a device for making microencapsulation cell, which comprises an injection system, a high-voltage pulse generator and an accessory system. The microcapsules prepared thereby can be applied for cell culturing and cell transplantation.

[Problem] To activate an abnormal mesenchymal stem cell whose therapeutic effect is lost or reduced, or rather which has a disease-exacerbating effect so as to be in a state suitable for cell transplant therapy.[Solution] An activator for mesenchymal stem cells, mesenchymal stem cells activated by the activator, a method for producing the same, and a pharmaceutical containing the activated mesenchymal stem cells are provided.

A method of treatment of neurodegenerative diseases using neuronal cell transplants is provided. The growth, survival and integration of the transplanted neuronal cells is enhanced by a method of culturing the neuronal cells with drugs having an affinity for immunophilins. Immunophilin binding drugs are optionally administered to the patient during transplantation and / or post-operatively. Neurotrophic factors can also be administered to the neuronal cells in vitro, or to the patient during the transplantation procedure and / or post-operatively.

The invention relates to an alginate-drug loaded nanoparticle-polycation microcapsule and preparation and application thereof. The microcapsule product is a spherical microcapsule with a particle sizeof 100 to 1000 microns. The structure of the microcapsule product is divided into two parts of a microcapsule membrane and an inner core. The microcapsule membrane is self-assembled layer by layer byalginate, drug-loaded nanoparticles and polycations to form a polyelectrolyte composite hydrogel film, and the inner core is a hydrogel or hydrosol environment containing animal cells. The microcapsule product is used as an immunosuppressive tool in embedding carriers for cell transplantation. Under the premise of ensuring the microcapsule strength and immuno-isolation performances, the surface roughness and surface charge of the microcapsule membrane can be reduced, the in-situ release of an anti-inflammatory drug on the surface of the microcapsule is realized, and the problem of fibrillation wrapping is solved from two aspects of stabilization of the microcapsule membrane by the drug-loaded nanoparticles and in-situ release of the anti-inflammatory drug for anti-inflammation.

The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one factor Xa inhibitor, preferably rivaroxaban, as well as at least one thrombin inhibitor, preferably bivalirudin.

The invention discloses an inhibition method for induced differentiation of hair follicle stem cells into vascular endothelial cells, comprising: (1), isolating rat hair follicle stem cell; (2), culturing the rat hair follicle stem cells; (3), purifying the rat hair follicle stem cells; (4), inhibiting the induced differentiation of the rat hair follicle stem cells into vascular endothelial cells. In the inhibition method provided herein, vascular endothelial cell growth factor 165 is used for the first time as an inducing factor so that the rat hair follicle stem cells efficiently and directionally differentiate into vascular endothelial cells; the formation and growth of vascular endothelial cells generated by induced differentiation of the hair follicle stem cells can be adjusted, an effective healing of a wound is promoted; it is also possible to provide seed cell sources for solving the problems in vascularization of tissue engineering skin, cell-transplant therapy of ischemic disease and the like.

Disclosed are novel peptides inhibitory of the activity of vascular endothelial growth factor (VEGF) and their use in the treatment of angiogenesis-related diseases, including cancer. A combinatorial library of peptides consisting of six amino acid residues were chemically synthesize and, from the library, specific amino acid residues for each amino acid position were screened by comparing their inhibitory activity against VEGF binding to the cell surface receptor. The novel peptide sequences thus obtained bind to VEGF and block the binding of VEGF to its receptors present on the surface of vascular endothelial cells, thereby inhibiting the hormonal activity of VEGF. The peptides inhibit the angiogenesis induced by VEGF and human cancer cells. Also, the peptides inhibit growth and metastasis of human cancer cells transplanted to mice. Thus, the peptides can be used to treat angiogenesis-related diseases, including cancer, diabetic retinopathy, rheumatoid arthritis, etc.

The invention relates to phenylbutyryl curcumin derivate and application thereof in anti-tumor drug preparation, in particular to 4-(di(2-chloroethyl) amino) phenylbutyryl curcumin, 4,4'-(di(2-chloroethyl)amino) diphenylbutyryl curcumin, pharmaceutically acceptable salts and a preparation method thereof, and applications of 4-(di(2-chloroethyl) amino) phenylbutyryl curcumin, and 4,4'-(di(2-chloroethyl)amino) di phenylbutyryl curcumin in anti-tumor drug preparation. The phenylbutyryl curcumin derivate can be used for (but not limited to) preparing drugs for treating leukemia, skin cancer, gastric cancer, colon cancer, liver cancer, breast cancer or prostatic cancer. The derivate has obvious inhibition on a plurality of animal tumor cell transplanting modules, especially for the human chronic granulocytic leukemia model constructed by NOD-SCID mice inoculated with the human chronic granulocytic leukemia K562 cell stain, the life prolonging rate is obviously enhanced, and the serious toxicity to mice does not exist.

This invention provides a efficiently new induction model of hepatic oval cell. In this model significantly inducing the production of embryonic stem cell endogenous oval cell by using HGF and EGF, the whole induction method is fairly convenient, induction cycle is also very short. Utilizing very little embryonic stem cell provenance source can induce to generate sufficient hepatic oval cell which is contented to clinical requirement by using the invented induction model of hepatic oval cell, it also can be used for clinical category such as hepatic oval cell transplant, hepatic tissue engineering and so on, it can play a part in assistant supportive treatment or curing disease for Liver function failure, hepatic metabolic disease caused by various kinds of reason.

The invention belongs to the technical field of medicine and pharmacy, and discloses an application of a micromolecule compound WZ-2-033 shown as below to medicines for treating breast cancer and stomach cancer. The compound can restrain proliferation, clone formation, migration and invasion of breast cancer cells and stomach cancer cells, and can induce apoptosis of the breast cancer cells and the stomach cancer cells. The compound exerts effects through influencing an STAT3 signal channel, can reduce the phosphorylation level (Y705) of the STAT3, can reduce STAT3 dimer formation, can reduceDNA combining capacity and transcriptional activity of the STAT3, and can further reduce the expression level of STAT3 target genes c-Myc, Bcl-xL and Mcl-1 so as to restrain activation of STAT3 signals and restrain the growth of the breast cancer cells and the stomach cancer cells. In an animal model, the compound can restrain the growth of stomach cancer cell transplanted tumors and has favorableapplication prospects.

Methods of treating individuals suspected of suffering from diseases, conditions or disorders of the Central Nervous System including nerve damage are provided wherein stable, homogeneous post-mitotic human neurons are into the individual's brain or at or near a site of nerve damage. Pharmaceutical compositions of stable, homogeneous post-mitotic human neurons and a pharmaceutically acceptable medium are also disclosed. Methods of generating non-human animal models of human CNS diseases, conditions or disorders by implanting stable, homogeneous post-mitotic human neurons into the brain of a non-human animal are disclosed. Non-human animals eith stable, homogeneous post-mitotic human neurons implanted in their brain are also disclosed.